At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 46 enrolled
Drug / intervention
Gefitinibdrug
Likely dose
Gefitinib 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multi-centre Study to Evaluate Efficacy and Safety of Gefitinib as the First-line Treatment for Locally Advanced (IIIB), Metastatic (IV) or Recurrent Pulmonary Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation.
In Brief
A Phase 2 clinical trial evaluating Gefitinib for Pulmonary Cancer. Completed, enrolled 46 participants across 2 sites.
Detailed Summary
The purpose of this study is to evaluate the overall objective tumor response rate (ORR) of Gefitinib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Cancer
CountriesSouth Korea
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2006
First PostedJun 2006
Primary CompletionDec 2007
TodayJul 2026
First PostedJun 27, 2006
Enrollment StartMar 1, 2006
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 20.0 years ago
Interventions
Gefitinibdrug
250mg tablet oral tablet once daily